1 such as antibiotics, that the lytic life cycle is activated to produce Stx2 19 and progeny phage 2 that can spread virulence genes to commensal E. coli species. 20 3 Instead of an antimicrobial strategy for killing pathogens, a genetic-based anti-virulence 4 strategy could neutralize virulence before expression and minimize resistance until the bacteria 5 has been completely shed from the gastrointestinal tract. Temperate phages offer a solution as 6 they are genetically engineerable and can integrate into the bacterial chromosome as 7 prophages for long-lasting effect as they confer fitness advantages to the bacterial host. 21 8 Instead of relying on a non-native constituent of the gut that could face practical barriers for 9 efficacy, temperate phages are abundantly found in human gut bacteria [22] [23] [24] and can constitute 10 large portions of the bacterial chromosome. 25 
11
To modify the function of specific species within the complex community in the 12 mammalian gut, in a manner that avoids the emergence of resistance, we report the use of a 13 genetically-engineered temperate phage to repress Stx from an established E. coli infection. Phages typically replicate by a lytic mechanism in which a bacterium infected by a 26 phage turns its cellular machinery towards producing phage components that assemble into 27 viral particles and are released upon cell lysis. This produces hundreds of progeny phage to 28 infect new bacterial hosts (Figure A, i-iii) . Lytic phages replicate solely by this life cycle and the 29 decimation of phage-susceptible bacteria selects for phage-resistant mutants that can 30 repopulate over time (Figure 1A, upper panel) . In contrast, temperate phages can also integrate 31 their genetic material into the host chromosome as a prophage to co-replicate with the 32 bacterial genome during cell proliferation (Figure 1A, . In a bacterial population, this leads 33 to the lysogenic conversion of phage-susceptible species that coexist with phage-resistant 34 species ( Figure 1A, lower panel) . Because anti-bacterial approaches can enrich for resistance, 35 5 including phage therapy which typically utilizes lytic phages, we aimed to engineer temperate 1 phages to deliver an anti-virulence payload that neutralizes virulence in a manner that 2 minimizes the selection for resistance.
3
To illustrate the feasibility of using a temperate phage, we show that bacteriophage l 4 transduces a substantial fraction of targeted bacteria in the mammalian gut. As shown in 5 Figure 1B , we used a streptomycin-treated mouse model to quantitate temperate phage 6 lysogeny on E. coli colonizing the mammalian gastrointestinal tract. One day after colonization 7 with E. coli MG1655, we introduced lBH1 phage by oral gavage and collected daily stool 8 samples for analysis of bacterial and phage titers. We constructed lBH1 from l phage by 9 inserting an antibiotic resistance cassette for quantification of lysogens ( Figure 2D ). After oral 10 administration of lBH1 phage, we found that fecal phage levels reached equilibrium 11 approximately two days later and persisted at substantial concentrations (> 10 6 pfu/g stool) for 12 the duration of the experiment ( Figure 1C ). As phage in the absence of its cognate bacterial 13 host is undetectable in the stool of mice ~2 days after administration, 26 our results indicate that 14 lBH1 phage is capable of continuous replication in the gut, enabling its expansion throughout 15 the bacterial population from a single dose. Furthermore, introduction of lBH1 phage did not 16 significantly alter fecal E. coli concentrations ( Figure 1D ), which is in sharp contrast to lytic 17 phages that can cause substantial reduction. 9 Using antibiotic selection, we quantified the 18 number of fecal E. coli harboring the lBH1 prophage and found a substantial fraction (~17 to 19 30%) remained lysogenized by days 7 to 10 ( Figure 1E ). Overall, these results indicate that the 20 temperate phage l is capable of widespread modification of its cognate bacteria in the gut. As gut bacteria harbor numerous prophages including those encoding virulence, 27 5 overcoming superinfection exclusion mechanisms is crucial for achieving efficacious in situ 6 transduction. For the foodborne pathogen EHEC, the lambdoid prophage, 933W, both 7 produces Stx2 and inhibits phage superinfection by other lambdoid phages. 28 To demonstrate 8 the efficacy of the in situ phage-based anti-virulence strategy, we aimed to neutralize Stx2 9 production from E. coli MG1655 lyosgenized by 933W (E. coli 933W ).
10
E. coli 933W excludes l phage infection but genetic hybrids of l with other lambdoid 11 phages restore infectivity. As shown schematically in Figure 2A , the 933W prophage inhibits 12 infection from l phage by recognition of its immunity region, i.e. indispensable genes 13 responsible for the lysis-lysogeny decision in the phage life cycle. Because lambdoid phages 14 have similarities in genetic function and organization despite dissimilar sequences, it is 15 feasible to replace the l immunity region with orthologous immunity regions from other 16 lambdoid phages to overcome the superinfection exclusion. 29 We found that the efficiency of 17 plating (EOP) of l phage against E. coli 933W was ~10 6 -fold lower than that of the non-lysogen 18 ( Figure 2B ), confirming its superinfection exclusion. We verified that this effect is not due to a 19 cI-based immunity ( Figure S1 ). We then tested the EOP for genetic hybrids of l phage in which 20 the l immunity region is swapped with that of other lambdoid phages (e.g. 21, 434, and P22),
21
( Figure S2 and Table S3 ). As shown in Figure 2B , these hybrid phages had substantially 22 improved EOPs against E. coli 933W with 6.0% for limm21 and 6.7% for limm434 phages.
23
Moreover, hybridization with the Salmonella phage P22 resulted in near complete recovery of 24 EOP to 78% for limmP22dis phage, indicating that lambdoid phages from non-cognate 25 bacterial hosts could be a reservoir for genetic orthologs that maintain phage function while 26 circumventing superinfection exclusion mechanisms. 
18
Efficient gene transduction enables the delivery of anti-virulence genes. We inserted 19 genes for 933W×cI indand a kanamycin resistant cassette (to quantitate lysogeny) into the non-20 essential b2 region of l, 30 producing lBH1 ( Figures 2D and S3 ). We confirmed that 933W×cI ind-21 expressed from lBH1 was functional ( Figure S4 ). To overcome superinfection exclusion from 22 the 933W prophage, we utilized a P22 immunity region instead of a l immunity region. A phage 23 cross between lBH1 and limmP22dis resulted in the replacement of ~6 kb of the immunity 24 region of lBH1 with a ~5 kb portion of that from limmP22dis while retaining 933W×cI indand 25 Kan R genes (Figures 2D and S3, and Table S3 ). This new phage, lBH2, showed improved EOP 26 to 90% ( Figure 2D ) and demonstrated a functional loss of l immunity and gain of P22 27 immunity, as well as expression of functional 933W×cI ind-( Figure S4 ).
29

Anti-virulence phage inhibits Stx2 production in vitro 30
Transcriptional repression delivered by lBH2 phage neutralizes Stx2 production. As 31 outlined in Figure 3A , we tested the efficacy of lBH2 phage to inhibit Stx2 production from E. 32 coli 933W by mixing them at equal concentrations (MOI~1) and culturing for 8 h. We found 33 significantly less Stx2 produced in E. coli 933W cultures treated with lBH2 phage compared to 34 those untreated ("buffer") or treated with limmP22dis phage, the parental phage of lBH2 that 10 is capable of infecting E. coli 933W but lacks the 933W×cI indgene ( Figure 3B ). Quantification of 1 bacterial concentrations over time show that E. coli 933W steadily grows over 8 h in the absence 2 of phage ("buffer") whereas introduction of limmP22dis results in an initial drop in titer during 3 the first 4 h followed by a recovery (Figure 4D , non-induced). For lBH2 phage, a similar drop in 4 bacterial concentration was associated with increased lysogenic conversion of E. coli 933W that 5 reached 70% by 4 h, indicating that both decreased bacterial titers and repressed Stx2 6 expression may contribute to the overall reduction of Stx2 concentration. To confirm that the 7 latter provides sustained anti-virulence effect, we isolated lBH2 lysogens of E. coli 933W , i.e. E. Figure 3E, induced) . To confirm that once lysogeny is established by lBH1 or lBH2 phage, 27 stx2 repression is maintained even in the presence of mitomycin c, we cultured lBH2 lysogens 28 of E. coli 933W for up to 8 h in the presence of mitomycin c ( Figure 3F ). In the case of lBH2 29 lysogens of E. coli 933W , we were unable to detect the toxin, indicating repression is maintained 30 under inducing conditions ( Figure 3H ). quantities of Stx that is otherwise too low to be detected in stool. Mice pre-colonized by E. coli 1 933W were orally treated with lBH2 phage and then received three doses of mitomycin c by 2 intraperitoneal injection to induce stx2 expression ( Figure 4A ). Daily fecal samples were 3 collected for analysis of bacterial and Stx2 concentrations. After mitomycin c injections, we 4 quantified fecal Stx2 and found that lBH2 treatment reduced fecal Stx2 titers compared to 5 buffer on days 3 and 4 with the latter showing statistical significance ( Figure 4B ). Furthermore, 6 mice receiving lBH2 phage showed a significant reduction in fecal Stx2 from day 3 to 4, 7 whereas buffer treated mice did not (p = 0.547; Wilcoxen test). Although lBH2 phage did not 8 completely repress Stx2 production, these are highly inducing non-physiological conditions 9 with fecal Stx2 concentrations (~10 2 to 10 3 ng Stx2/g mouse stool) in excess of those 10 encountered in human Stx-producing E. coli infections (~2-50 ng Stx2/mL human stool). 1 11 lBH2 phage lysogenizes E. coli 933W and does not affect its titer in the murine gut.
12
Quantification of total fecal E. coli 933W did not reveal markedly different concentrations between 13 buffer and lBH2 treated mice ( Figure 4C ). Quantification of fecal E. coli 933W lysogenized by 14 lBH2 (Figure 4D ) showed that a substantial fraction of the population was transduced, with 15 geometric means between ~0.9% to 2.6% and individual samples reaching as high as 71%. colonizing the gut. We genetically engineer temperate phage l to express a repressor that 2 neutralizes Stx production in E. coli and take advantage of the genetic mosaicism of lambdoid 3 phages to create a hybrid phage that is capable of overcoming phage resistance mechanisms.
4
We found that our anti-virulence phage not only efficiently infects, lysogenizes and inhibits Stx2 5 production from E. coli in vitro, but is also effective at propagating in the murine gut from a 6 single dose to significantly reduce Stx2 production in vivo.
7
With the complexity and interconnectedness of microbes in the gut, perturbations can 8 have unexpected consequences. Modulating the impact of a bacterial species by manipulating 9 its concentration can lead to unintended cascading effects mediated by inter-bacterial or 10 bacterial-host interactions. While the typical strategy is to eliminate a particular bacteria, it is 11 usually a specific function performed by this bacteria that is deleterious. By precisely and 12 robustly modifying this individual function, a therapeutic effect can persist while minimizing 13 disruption to the surrounding microbiota and avoiding the selection for resistance. Herein we 14 report a framework for making precise genetic modifications that can be practically applied to 15 bacteria within a complex biological system such as the gut microbiome.
16
For treating pathogenic bacterial infections, disarming their pathogenicity by targeting 17 virulence factors provides a direct therapeutic strategy. With the impending crisis of 18 antimicrobial resistant infections, new strategies for combating pathogens are desperately 19 needed. By aiming to repress virulence factors instead of relying on anti-bacterial effect, the 20 selection pressures for resistance are minimized. Furthermore, using a genetic-based 21 approach makes it feasible to rationally design anti-virulence strategies that target one or 22 multiple virulence factors to improve therapeutic efficacy.
23
As we gain greater insight into the importance of the gut microbiota to health and its 24 inter-individual diversity and complexity, modification of specific bacteria within this community 25 requires a thoughtful and nuanced approach that maximizes therapeutic efficacy and 26 minimizes collateral effect. Our work illustrates a framework by which bacteria can be 27 specifically modulated in situ with rationally designed function in a manner alternative to 28 present approaches and could inspire strategies for treating recalcitrant bacterial infections. 
5
To study of the effect of temperate phage on non-pathogenic E. coli in the mouse gut 6 ( Figure 2) , mice received 5 g/L of streptomycin sulfate (Gold Bio) in their drinking water which 7 was replaced every 2-3 days. On day 0, 100 µL of streptomycin-resistant E. coli MG1655 was 8 administered to mice by oral gavage. The bacterial gavage solution was prepared from an 9 overnight culture in LB, washed twice with PBS, and then diluted 100-fold into PBS, yielding 10 ~10 7 cfu/mL. One day later (day 1), mice received 100 µL of lBH1 phage which consisted of a 11 5 x 10 7 pfu/mL solution diluted 1:10 into 100 mM sodium bicarbonate immediately prior to 12 gavage. Daily stool samples were collected for microbial quantification. To quantify fecal 13 phage, fresh non-frozen samples were gently suspended into 1 mL of phage buffer, incubated 14 at 4°C for ~10 min with a few drops of chloroform, and then pelleted at 4000 rpm at 4°C.
15
Phage concentration was determined using a double-agar overlay plaque assay 36 in which 16 serially diluted phage solutions were incubated for 20 min at r.t. with a hardened overlay of E. 17 coli MG1655 in 0.3% agar in TNT media over a 1.5% agar in TNT base. After aspiration, plates 18 were incubated at 37°C overnight after which plaques were counted. To quantify fecal E. coli, 19 frozen stool was thawed from -80°C and suspended into 1 mL of PBS by vortexing for 10 min 20 at 4°C followed by low-speed centrifugation at 200 rpm for 20 min to settle fecal debris. The 21 fecal suspension was then serially diluted into PBS and 100 µL was plated onto MacConkey 22 agar (Remel) plates supplemented with 100 µg/mL streptomycin sulfate to quantify total E. coli 23 or supplemented with 100 µg/mL streptomycin and 50 µg/mL kanamycin to quantify lBH1 24 lysogens of E. coli.
25
To study the effect of the engineered temperate phage on Stx2-producing E. coli, mice 26 were treated with similar conditions as described above with the following modifications. On 27 day 0, mice received 100 µL of similarly prepared streptomycin-resistant E. coli 933W in PBS by 28 oral gavage. On day 1, mice received 100 µL of lBH2 phage, which was a 5 x 10 10 pfu/mL 29 solution diluted 1:10 into 100 mM sodium bicarbonate immediately prior to gavage. On day 2, 30 to induce Stx2 expression from engrafted E. coli, mice received three intraperitoneal injections 31 of 0.25 mg/kg of mitomycin c at 3 h intervals. 32 Stool samples were collected daily and stored 32 at -80°C until analysis. Fecal E. coli was quantified by plating as described above and fecal 33 Stx2 was quantified from the same suspension of stool in PBS by mixing 10:1 with 20 mg/mL 17 of polymyxin B, incubating at 37°C for ~20 min and then storing at -20°C until analysis by 1 ELISA as described below.
2 3 4 Bacterial strains. A table of bacteria used in this study is listed in Table S1 . E. coli 933W was 5 generated by a previously described method, 37 in which 933W phage was produced from the 6 supernatant of a log phase culture of E. coli O157:H7 strain edl933 in a modified LB media (10 7 g/L tryptone, 5 g/L yeast extract, 5 mM sodium chloride, 10 mM calcium chloride, and 0.001% 8 thiamine) and then stored at 4°C. Molten top agar containing 100 µL of E. coli MG1655 and 3 9 mL of modified LB media with 0.3% agar at 45°C was poured onto plates of modified LB agar 10 and allowed to harden. Supernatants of E. coli O157:H7 cultures were then spotted onto the 11 top agar and incubated at 37°C overnight. Resulting plaques were picked and re-streaked onto 12 LB. Successful 933W lysogens of E. coli were identified by screens for resistance to 13 limm933W and the PCR amplification of the cI to cro region of 933W (fwd-14 agccactcccttgcctcg; rev-gcttatttcaagcatttcgcttgc). E. coli lysogens of l and limm933W were 15 generated similarly using TNT media instead of modified LB media and screened for successful 16 lysogeny by resistance to l or limm933W, respectively, and ability to produce phage progeny.
18
Preparation of high titer phage stocks. Phage was propagated via the double agar overlay 19 method where 100 µL of serially-diluted phage in phage buffer was mixed with 100 µL of E. coli 20 MG1655 for ~20 min at r.t., then mixed with 3 mL of molten top agar (TNT media with 0.3% top 21 agar at 45°C) and poured onto pre-warmed plates of TNT agar. After incubation overnight at 22 37°C, top agar from plates with the highest density of plaques were suspended into 5 mL of 23 phage buffer and then gently rocked at 4°C for ~2 hrs. Supernatants were sterile filtered to 24 yield ~10 9 to 10 10 pfu/mL of phage. Phage stocks were stored at 4°C.
26
Phage strains. A table of phage used in this study is listed in Table S2 . lBH1 phage was 27 generated using the inherent lred recombination system of l phage expressed during lytic 28 replication. A crude phage lysate containing recombinant phage was produced by mixing 100 29 µL of E. coli C600, containing a plasmid vector with Tn5-933W×cI indflanked by 400 bp 30 homology to ea59 and ea47 in a pJET1.2 backbone (Table S3) , with 100 µL of serially-diluted l 31 phage, incubated for 20 min at r.t. followed by addition with 3 mL of molten top agar (TNT 32 media with 0.3% top agar at 45°C) and poured onto TNT agar plates. After overnight 33 incubation at 37°C, top agar from the plate with the greatest plaque density was resuspended 34 into 5 mL of phage buffer (50 mM tris, 100 mM sodium chloride, 10 mM magnesium sulfate, 35 18 and 0.01% gelatin, pH 7.5), sterile filtered, and stored at 4°C. To isolate the recombinant 1 phage, 50 µL of crude phage lysate was mixed with 50 µL of E. coli C600 grown to log-phase 2 in LB and incubated for ~3 h at 37°C. After incubation, 100 µL was plated onto LB containing 3 50 µg/mL of kanamycin and grown overnight at 37°C with individual colonies re-streaked 4 twice. To additionally purify by plaque purification, colonies were grown overnight in LB and 5 their sterile filtered supernatants were spotted onto TNT top agar of E. coli C600. Individual 6 plaques were streaked onto LB containing 50 µg/mL of kanamycin and sequenced to confirm 7 insertion in the correct locus of l phage. 8 lBH2 phage was generated by a phage cross between lBH1 phage and limmP22dis 9 phage. 200 µL of a log phase E. coli C600 culture (7 x 10 7 cfu/mL) in T-broth (1% tryptone and 10 0.5% sodium chloride) with 0.4% maltose was mixed with a 200 µL solution of lBH1 phage
11
(1.5 x 10 8 pfu/mL) and limmP22dis (1.5 x 10 8 pfu/mL) in phage buffer. After static incubation at 12 37°C for 20 min, this mixture was diluted 100-fold into pre-warmed T-broth with 1% glucose 13 and cultured with shaking at 37°C for 90 min. The culture was treated with drops of chloroform, 14 pelleted, and then the supernatant was sterile-filtered to produce a crude phage lysate.
15
Residual chloroform was minimized by crossflowing air (Millipore Steriflip) at r.t. for 1 h. 10 mL 16 of this phage lysate was mixed with 1 mL of mid-log culture of a l lysogen of E. coli C600 17 grown in LB with 0.4% maltose, incubated at 37°C for 20 min. After ~30-fold concentration by 18 centrifugation, 200 µL was plated onto LB containing 50 µg/mL of kanamycin. Resulting
19
colonies were re-streaked twice and then tested for phage immunity by spot testing 5 µL of 20 phage against a top agar containing each candidate colony. Correctly engineered phages, as 21 lysogens, were identified from colonies by susceptibility to limm434 (positive control) but 22 resistance to limm933W (presence of 933WcI indgene) and resistance to limmP22dis 23 (presence of P22 immunity region). Phage lysates were prepared by culturing colonies 24 overnight in TNT media, pelleting and sterile filtering the supernatant, and then incubating 100 25 µL of this phage mixture with 100 µL of E. coli C600 (MOI~0.1) at 37°C for 20 min and then 26 plating onto LB with 50 µg/mL of kanamycin. After overnight incubation at 37°C, phage was 27 plaque purified by preparing phage lysates from individual colonies as described above and 28 streaking 10 µL onto hardened top agar containing E. coli C600. After overnight incubation at 29 37°C, individual plaques were picked and restreaked onto LB with kanamycin. The resultant 30 lBH2 lysogen of E. coli was confirmed susceptible to l and limm434 as well as resistant to 31 limm933W and limmP22dis ( Figure S4 ). Sequencing confirmed the presence of the P22 32 immunity region and 933WcI indgene ( Figure S3 and Table S3 ).
34 19
Quantifying phage and efficiency of plating. The infectivity of phage against E. coli was 1 quantified by the double overlay agar method in which E. coli MG1655 or E. coli 933W was 2 cultured overnight in TNT media, diluted 1:100 into fresh TNT media and cultured until mid-log 3 phase of which 50 µL was mixed with 700 µL of molten top agar (TNT media with 0.5% agar at 4 45°C) and poured into individual wells of a 6-well plate containing pre-poured TNT media with 5 1.5% agar. After hardening, 100 µL of phage serially-diluted in phage buffer was added and 6 incubated for 20 min at r.t. followed by aspiration. Plates were incubated at 37°C overnight and 7 then examined for titers of plaque forming units. Efficiency of plating was calculated as the titer 8 of phage on the E. coli 933W divided by its titer on the non-lysogenic E. coli.
10
In vitro assay of phage effect. E. coli 933W was cultured overnight in TNT media at 37°C, then 11 cells were washed once with fresh TNT media and diluted to OD600nm = 0.1 (~8 x 10 7 cfu/mL). At 12 t = 0, 5 mL of E. coli suspension was mixed with 1 mL of 4 x 10 8 pfu/mL of lBH2 or 13 limmP22dis phage solution. To quantify E. coli concentrations in solution, aliquots were 14 collected, serially-diluted into PBS and the spotted (10 µL) onto LB or LB with 50 µg/mL 15 kanamycin plates to quantify total E. coli and lBH2 lysogens, respectively. After 8 h, aliquots 16 were mixed 10:1 with 20 mg/mL of polymyxin B, incubated at 37°C for ~20 min and stored at -17 20°C for quantification of Stx2 by ELISA.
18
Stx2 concentrations in cultures of E. coli 933W , its lBH1 lysogen, or its lBH2 lysogen 19 were prepared similarly as described to above, where overnight cultures were washed with 20 fresh TNT media and diluted to OD600nm = 0.1. During incubation at 37°C, aliquots were 21 collected, mixed with polymyxin B and stored at -20°C for quantification of Stx2 by ELISA. 
31
The antibody-enzyme conjugate was previously prepared using an HRP conjugation kit (Abcam 32 #ab102890) with a rabbit anti-Stx2 antibody (List Biological Labs, #765L) according to the 33 manufacturer's protocol. After washing thrice with PBST, 100 µL/well of colorimetric reagent 1 of 2M H2SO4 to stop the reaction. Absorbance was measured at 450 nm. 
